| 7 0.5 (7.69%) | 06-17 13:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.65 |
1-year : | 10.1 |
| Resists | First : | 7.4 |
Second : | 8.65 |
| Pivot price | 6.58 |
|||
| Supports | First : | 6.3 |
Second : | 5.63 |
| MAs | MA(5) : | 6.56 |
MA(20) : | 6.55 |
| MA(100) : | 10.75  |
MA(250) : | 8.79 |
|
| MACD | MACD : | -0.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 66.7 |
D(3) : | 57 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 16.45 | Low : | 4.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRDA ] has closed below upper band by 18.6%. Bollinger Bands are 68.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.62 - 6.66 | 6.66 - 6.68 |
| Low: | 6.29 - 6.33 | 6.33 - 6.35 |
| Close: | 6.44 - 6.5 | 6.5 - 6.55 |
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Fri, 12 Jun 2026
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan
Fri, 12 Jun 2026
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Fri, 12 Jun 2026
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Fri, 12 Jun 2026
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Fri, 12 Jun 2026
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Thu, 04 Jun 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 1.95e+007 (%) |
| Held by Institutions | 12.3 (%) |
| Shares Short | 998 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7256e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 834.6 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 5.74e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 1.73e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|